Delighted to be back in Institut Pasteur de Dakar for the kick-off of our EDCTP3 supported PvSeroRDT consortium. We will develop a new diagnostic test for detecting P. vivax malaria hypnozoites and set up manufacturing capacity with Diatropix in Senegal.

Enormous thanks to our Senegalese hosts 🇸🇳

Beautiful study of primaquine treatment to prevent vivax malaria relapses from Jean Popovici's team from Pasteur Cambodia.

The study is special because patients were moved to a non-endemic part of Cambodia, excluding reinfection from msoquitoes.

authors.elsevier.com/sd/article/S...

With colleagues from @pasteur.fr, we ran a case-control study of people infected with SARS-CoV-2 (omicron) in Paris.

We found Abs correlate with protection in serum (known for a long time) but also in saliva (obvious, but rarely demonstrated).

academic.oup.com/ofid/article...

We expect large proportional reductions in low transmission settings. When transmission is higher, we expect smaller proportional reductions (although there are more cases to prevent).

When PQ adherence is low, there's a benefit to switching to TQ.

New work from Conni Ciavarella estimating effectiveness of primaquine and tafenoquine against P. vivax malaria.

From clinical studies, we know PQ & TQ prevent relapses in treated individuals.

We used a model to assess the population impact of these drugs.

www.sciencedirect.com/science/arti...

We even convinced Luminex to sponsor the event.

Happy to be spending a few days in Chantilly for the annual retreat of Institut Pasteur’s Department of Global Health. So many talented students and post-docs presenting work on epidemiology, anti microbial resistance, social science, modelling and more.

A real pleasure to see Maria Yazdanbakhsh today at Institut Pasteur’s Future in Parasitology meeting.

So much variation in vaccine-induced immunity between Europeans and Africans!